Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchUniversities and Colleges without Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

Federal University of São Paulo (UNIFESP)

8 Trials1 Paper

The Federal University of São Paulo (UNIFESP) is a public federal research university based in the state of São Paulo, Brazil, with multiple campuses and a strong reputation in health sciences and related programs.

Academic Research

1 papers

Published Papers

1

Trial Involvement

8

Distinct Focus Topics

0

Latest Publication

Feb 1, 2018

Recent Papers

Quick Facts

Website
Visit

Sponsored Trials

6
RecruitingII

Ayahuasca, Esketamine and PTSD

Start Date
Compounds
Ayahuasca, Esketamine
RecruitingNA

Ayahuasca, Esketamine and Body Image Perception

Start Date
Compounds
Ayahuasca, Esketamine
RecruitingNA

Ayahuasca, Esketamine and Premenstrual Symptoms

Start Date
Compounds
Ayahuasca, Esketamine
Not yet recruitingIII

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

Start Date
Compounds
Ketamine, Placebo
CompletedII

Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial

Start Date
Compounds
Ibogaine, Placebo
Unknown statusIV

Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression (KETProject)

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

2
CompletedII

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

Start Date
Compounds
Ibogaine
CompletedI, II

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

Start Date
Compounds
Ayahuasca, Placebo

Research Papers

1
Open AccessindividualLong-term follow-up

Longterm effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up

This qualitative follow-up study (n=8) interviewed patients 4-7 years after the intake of ayahuasca (123.2 mg DMT, 32.34mg Harmine) within the context of a previous open-label study; most patients reported that the experience was among the most important of their lives, but no long-term improvements in depression scores (MADRS) were found.

Published
Journal
Archives of Clinical Psychiatry (São Paulo)
Authors
Dos Santos, R. G., Osório, F. L., Hallak, J. E.